摘要
目的: 探讨贲门癌术前短期化疗与远期生存的关系。方法: 贲门腺癌患者60 例, 随机分成用药组与对照组,每组30 人。用药组术前分次服用氟脲嘧啶多相脂质体,总剂量为500ml。对两组手术切除标本进行大体和病理组织学检查,以及流式细胞荧光DNA 凋亡细胞率的检测。结果:与对照组比较,用药组肿瘤体积缩小。癌细胞发生显著的退行性变和坏死。DNA 凋亡细胞率明显高于对照组 ( P< 0 .001) 。5 年生存率, 用药组为40 .0 % , 对照组为23 .3 % 。结论:上述结果表明贲门癌患者术前短期服用氟脲嘧啶多相脂质体能提高术后5 年生存率。
Objective: To study the relationship between preoperative chemotherapy and the remote survival of 60 cases of cardiac cancer. Methods: Sixty patients with cardiac adenocarcinoma were divided into two groups. Thirty of them were treated with 500ml of FPLC (fluorouracil polyphase liposome composite) preoperatively and the others without as control. The resected specimens were examined macroscopically as well as microscopically,and the DNA apoptosis rate was examined by flow cytometry. Results: Compared with the control group, the tumors of treated group were smaller in size and with degeneration and necrosis. The DNA apoptosis cell rate was more marked. The postoperative 5-year survival rate was 40%in the treated group and 23.3%in the control group (P< 0.01). Conclusion: The above results suggest that the short-term reoperative chemotherapy with FPLC might increase the postoperative survival rate of patients with cardiac cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1999年第10期747-749,共3页
Chinese Journal of Clinical Oncology
基金
河北省科委科研基金!资助(93216107)
关键词
氟脲嘧啶
贲门腺癌
术前治疗
远期生存
FPLC Cardiac adenocarcinoma Neoadjuvant chemotherapy Survival